Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir Triple Therapy in Genotype 1 Chronic Hepatitis C
NCT01591460Phase 4Completed
- Sponsor
- Roche
- Start
- Aug 2012
- Primary completion
- Jun 2014
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of boceprevir in hepatitis C (HCV), sponsored by Roche. Primary endpoint: Sustained Virological Response at 12 Weeks After End of Treatment. Started Aug 2012; status: completed.
02
Drugs
boceprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01591460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01591460.